Accessibility Menu
Pacira BioSciences Stock Quote

Pacira BioSciences (NASDAQ: PCRX)

$22.02
(-4.3%)
-1.00
Price as of October 21, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$22.02
Daily Change
(-4.3%) $1.00
Day's Range
$19.84 - $22.88
Previous Close
$22.02
Open
$22.83
Beta
0.63
Volume
1,978,125
Average Volume
632,870
Market Cap
1B
Market Cap / Employee
$23.02M
52wk Range
$16 - $27.64
Revenue
-
Gross Margin
0.70%
Dividend Yield
N/A
EPS
-$2.79
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Pacira BioSciences Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PCRX+27.06%-59.45%-16.52%+228%
S&P+15.06%+95.03%+14.29%+415%

Pacira BioSciences Company Info

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$181.10M1.7%
Gross Profit$125.91M5.4%
Gross Margin69.53%2.4%
Market Cap$1.11B-16.9%
Market Cap / Employee$1.40M0.0%
Employees79011.0%
Net Income-$4.85M-125.7%
EBITDA$36.46M-26.9%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$300.48M21.6%
Accounts Receivable$114.37M9.2%
Inventory148.243.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$419.39M-34.4%
Short Term Debt$212.02M2217.4%

Ratios

Q2 2025YOY Change
Return On Assets-8.01%-12.0%
Return On Invested Capital2.61%-1.3%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$9.32M-82.0%
Operating Free Cash Flow$12.01M-77.4%

Valuation

MetricQ4 2023Q1 2024Q2 2024YoY Change
Price to Earnings43.5020.9822.24-
Price to Book0.931.161.481.39-7.14%
Price to Sales1.001.321.651.54-26.51%
Price to Tangible Book Value2.252.813.263.23-36.83%
Price to Free Cash Flow TTM3.595.177.259.2818.58%
Enterprise Value to EBITDA20.9721.2353.8034.892.88%
Free Cash Flow Yield27.9%19.3%13.8%10.8%-15.67%
Return on Equity-11.5%-12.1%-12.3%-15.6%-306.58%
Total Debt$644.42M$638.85M$636.46M$631.40M-2.65%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.